• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血浆或血清 TIMP-1 是结直肠癌生存结局的预测因子:一项荟萃分析。

Plasma or serum TIMP-1 is a predictor of survival outcomes in colorectal cancer: a meta-analysis.

机构信息

Department of Pathology, Korea University Ansan Hospital, Ansan-Si, Republic of Korea.

出版信息

J Gastrointestin Liver Dis. 2011 Sep;20(3):287-91.

PMID:21961097
Abstract

BACKGROUND AND AIMS

Tissue inhibitor of metalloproteinase-1 (TIMP-1) is a small secretory glycoprotein with anti-apoptosis and anti-matrix metalloproteinase activity. There have been some discordant data regarding the value of TIMP-1 as a prognostic factor in colorectal cancer (CRC) patients. To address this controversy, we conducted a meta-analysis for the relationship between TIMP-1 levels and overall survival in CRC.

METHODS

We selected the relevant published studies using citation databases including PubMed, Science Citation Index, and Conference Papers Index. The effect sizes of TIMP-1 on the patient's overall survival and TNM stages were calculated by hazard ratio (HR) or odds ratio (OR), respectively. The effect sizes were combined using a random-effects model.

RESULTS

Survival outcomes between high and low plasma or serum TIMP-1 levels were compared by uni- and multivariate analyses involving 1,477 and 1,359 CRC patients, respectively. CRC patients with high plasma or serum TIMP-1 levels showed poor survival rates compared to patients with low plasma or serum TIMP-1 in the uni- and multivariate analyses (HR, 2.2 and 2.1; P < 0.001). In addition, high TIMP-1 expression in colon cancer tissues was significantly associated with worse survival outcomes in 438 CRC patients (HR = 1.4; P = 0.017).

CONCLUSION

Plasma or serum TIMP-1 levels predict survival outcomes of CRC patients.

摘要

背景与目的

组织金属蛋白酶抑制剂-1(TIMP-1)是一种具有抗细胞凋亡和抗基质金属蛋白酶活性的小分泌糖蛋白。关于 TIMP-1 作为结直肠癌(CRC)患者的预后因素的价值,存在一些不一致的数据。为了解决这一争议,我们进行了荟萃分析,以评估 TIMP-1 水平与 CRC 患者总生存率之间的关系。

方法

我们使用引文数据库(包括 PubMed、科学引文索引和会议论文索引)选择了相关的已发表研究。使用风险比(HR)或优势比(OR)分别计算 TIMP-1 对患者总生存率和 TNM 分期的效应大小。使用随机效应模型对效应大小进行合并。

结果

通过涉及 1477 例和 1359 例 CRC 患者的单变量和多变量分析,比较了高和低血浆或血清 TIMP-1 水平之间的生存结果。与低血浆或血清 TIMP-1 相比,高血浆或血清 TIMP-1 水平的 CRC 患者在单变量和多变量分析中均显示出较差的生存率(HR,2.2 和 2.1;P <0.001)。此外,在 438 例 CRC 患者中,结肠癌组织中高 TIMP-1 表达与更差的生存结局显著相关(HR=1.4;P=0.017)。

结论

血浆或血清 TIMP-1 水平可预测 CRC 患者的生存结局。

相似文献

1
Plasma or serum TIMP-1 is a predictor of survival outcomes in colorectal cancer: a meta-analysis.血浆或血清 TIMP-1 是结直肠癌生存结局的预测因子:一项荟萃分析。
J Gastrointestin Liver Dis. 2011 Sep;20(3):287-91.
2
Serum TIMP-1 predicts survival outcomes of invasive breast carcinoma patients: a meta-analysis.血清 TIMP-1 预测浸润性乳腺癌患者的生存结局:一项荟萃分析。
Arch Med Res. 2011 Aug;42(6):463-8. doi: 10.1016/j.arcmed.2011.09.006. Epub 2011 Sep 23.
3
High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.术前血浆金属蛋白酶组织抑制因子-1水平高与结直肠癌患者的生存期短相关。
Clin Cancer Res. 2000 Nov;6(11):4292-9.
4
Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.循环明胶酶与金属蛋白酶组织抑制因子-1在结直肠癌肝转移疾病中的作用
Eur J Surg Oncol. 2006 Sep;32(7):756-63. doi: 10.1016/j.ejso.2006.03.028. Epub 2006 May 2.
5
Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.术前血清基质金属蛋白酶(MMP - 2、MMP - 9)及基质金属蛋白酶组织抑制剂(TIMP - 1、TIMP - 2)分析在结直肠癌中的价值有限。
Anticancer Res. 2000 Mar-Apr;20(2B):1085-91.
6
A novel prognostic index in colorectal cancer defined by serum carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1.一种由血清癌胚抗原和血浆基质金属蛋白酶组织抑制剂-1定义的新型结直肠癌预后指数。
Scand J Gastroenterol. 2010;45(2):200-7. doi: 10.3109/00365520903429406.
7
Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer.金属蛋白酶组织抑制剂-1在结直肠癌术后监测中的应用
Eur J Cancer. 2006 Aug;42(12):1889-96. doi: 10.1016/j.ejca.2006.01.058. Epub 2006 Jun 30.
8
Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.血清基质金属蛋白酶组织抑制因子-1与转移性乳腺癌患者对芳香化酶抑制剂来曲唑和他莫昔芬的反应
J Clin Oncol. 2008 Jun 1;26(16):2653-8. doi: 10.1200/JCO.2007.15.4336. Epub 2008 Apr 28.
9
Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer.基质金属蛋白酶-1组织抑制剂对结直肠癌患者血浆的预后影响
Anticancer Res. 2004 May-Jun;24(3b):2101-5.
10
Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study.术前血浆 TIMP-1 是原发性结直肠癌患者的独立预后指标:一项前瞻性验证研究。
Eur J Cancer. 2010 Dec;46(18):3323-31. doi: 10.1016/j.ejca.2010.06.009. Epub 2010 Jul 7.

引用本文的文献

1
Elucidation of the mechanism Underlying the promotion of ferroptosis and enhanced antitumor immunity by citrus polymethoxyflavones in CRC cells.阐明柑橘多甲氧基黄酮在结直肠癌细胞中促进铁死亡和增强抗肿瘤免疫的潜在机制。
Front Pharmacol. 2025 Apr 11;16:1571178. doi: 10.3389/fphar.2025.1571178. eCollection 2025.
2
Tissue inhibitor of metalloproteinase 1 as a biomarker of venous invasion in pancreatic ductal adenocarcinoma.金属蛋白酶组织抑制剂1作为胰腺导管腺癌静脉侵犯的生物标志物
Am J Cancer Res. 2025 Mar 15;15(3):1248-1263. doi: 10.62347/OVUJ4436. eCollection 2025.
3
FAM83B promotes the invasion of primary lung adenocarcinoma via PI3K/AKT/NF-κB pathway.
FAM83B 通过 PI3K/AKT/NF-κB 通路促进原发性肺腺癌的侵袭。
BMC Pulm Med. 2023 Jan 23;23(1):32. doi: 10.1186/s12890-022-02303-5.
4
Associations between matrix metalloproteinase, tissue inhibitor of metalloproteinase and collagen expression levels in the adjacent rectal tissue of colorectal carcinoma patients.结直肠癌患者相邻直肠组织中基质金属蛋白酶、金属蛋白酶组织抑制剂与胶原蛋白表达水平之间的关联。
Mol Clin Oncol. 2022 Feb;16(2):41. doi: 10.3892/mco.2021.2475. Epub 2021 Dec 21.
5
Comprehensive Omics Analysis of a Novel Small-Molecule Inhibitor of Chemoresistant Oncogenic Signatures in Colorectal Cancer Cell with Antitumor Effects.全面组学分析新型小分子抑制剂对结直肠癌细胞耐药致癌特征的抗肿瘤作用
Cells. 2021 Aug 3;10(8):1970. doi: 10.3390/cells10081970.
6
Integrative Gene Expression Profiling Analysis to Investigate Potential Prognostic Biomarkers for Colorectal Cancer.整合基因表达谱分析探讨结直肠癌潜在的预后生物标志物。
Med Sci Monit. 2020 Jan 1;26:e918906. doi: 10.12659/MSM.918906.
7
A Snapshot of The Tumor Microenvironment in Colorectal Cancer: The Liquid Biopsy.结直肠癌肿瘤微环境概述:液体活检。
Int J Mol Sci. 2019 Nov 29;20(23):6016. doi: 10.3390/ijms20236016.
8
Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance.结直肠癌中的系统性炎症:潜在因素、影响和预后意义。
World J Gastroenterol. 2019 Aug 21;25(31):4383-4404. doi: 10.3748/wjg.v25.i31.4383.
9
Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors.肿瘤细胞外基质重塑:作为实体瘤诊断和预后的循环工具的新视角。
Cells. 2019 Jan 23;8(2):81. doi: 10.3390/cells8020081.
10
TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer: A meta-analysis.TIMP-1 是一种新型的结直肠癌血清生物标志物:一项荟萃分析。
PLoS One. 2018 Nov 20;13(11):e0207039. doi: 10.1371/journal.pone.0207039. eCollection 2018.